Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $930.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective lifted by Jefferies Financial Group from $870.00 to $930.00 in a research note released on Thursday,Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.

Several other research analysts have also recently weighed in on REGN. Cantor Fitzgerald boosted their price objective on shares of Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the stock an “overweight” rating in a research report on Friday, July 31st. Wall Street Zen upgraded Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Sunday, September 20th. Royal Bank Of Canada reissued a “sector perform” rating and issued a $737.00 target price on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 29th. Morgan Stanley boosted their target price on Regeneron Pharmaceuticals from $730.00 to $758.00 and gave the stock an “equal weight” rating in a research report on Friday, July 31st. Finally, Wells Fargo & Company upped their price target on Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the company an “equal weight” rating in a research note on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $809.50.

Regeneron Pharmaceuticals Stock Up 0.1%

Shares of NASDAQ:REGN opened at $735.20 on Thursday. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06. The firm has a market cap of $75.70 billion, a P/E ratio of 18.17, a P/E/G ratio of 1.41 and a beta of 0.16. Regeneron Pharmaceuticals has a 12 month low of $541.00 and a 12 month high of $859.34. The company’s 50-day moving average price is $788.30 and its two-hundred day moving average price is $720.93.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, topping analysts’ consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The company had revenue of $4.29 billion during the quarter, compared to the consensus estimate of $3.82 billion. During the same period in the previous year, the firm posted $12.81 earnings per share. The company’s revenue was up 16.7% on a year-over-year basis. As a group, research analysts forecast that Regeneron Pharmaceuticals will post 45.34 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th were paid a $0.94 dividend. The ex-dividend date of this dividend was Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 9.29%.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Huda Y. Zoghbi sold 800 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $640,000.00. Following the transaction, the director owned 1,703 shares of the company’s stock, valued at $1,362,400. This represents a 31.96% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marion Mccourt sold 1,215 shares of the firm’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total value of $1,032,750.00. Following the completion of the transaction, the executive vice president owned 13,134 shares in the company, valued at $11,163,900. This represents a 8.47% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 3,946 shares of company stock valued at $3,302,458. 6.97% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. CX Institutional lifted its stake in Regeneron Pharmaceuticals by 30.1% in the third quarter. CX Institutional now owns 501 shares of the biopharmaceutical company’s stock valued at $380,000 after buying an additional 116 shares during the period. Versant Capital Management Inc grew its position in shares of Regeneron Pharmaceuticals by 55.2% during the 3rd quarter. Versant Capital Management Inc now owns 534 shares of the biopharmaceutical company’s stock worth $405,000 after buying an additional 190 shares during the period. Envestnet Asset Management Inc. grew its position in shares of Regeneron Pharmaceuticals by 0.6% during the 2nd quarter. Envestnet Asset Management Inc. now owns 109,838 shares of the biopharmaceutical company’s stock worth $68,488,000 after buying an additional 686 shares during the period. Andra AP fonden increased its stake in shares of Regeneron Pharmaceuticals by 583.2% in the 2nd quarter. Andra AP fonden now owns 28,912 shares of the biopharmaceutical company’s stock valued at $18,028,000 after acquiring an additional 24,680 shares during the last quarter. Finally, State Street Corp increased its stake in shares of Regeneron Pharmaceuticals by 3.6% in the 2nd quarter. State Street Corp now owns 4,834,688 shares of the biopharmaceutical company’s stock valued at $3,014,621,000 after acquiring an additional 170,210 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Sanofi alliance expanded, with substantial upfront and milestone potential. Sanofi will pay Regeneron $1 billion upfront and up to $7 billion in additional milestones for four next-generation, long-acting antibodies targeting type 2 inflammation. The companies will share development and commercialization costs and future profits, strengthening Regeneron’s immunology pipeline beyond Dupixent. Sanofi pays Regeneron up to $8B to expand immunology alliance
• Positive Sentiment: Weight-loss combination data address a key GLP-1 concern. In the Phase 2 COURAGE trial, trevogrumab preserved approximately 70% of the muscle lost by patients receiving semaglutide alone in an MRI substudy. The result could give Regeneron a differentiated position in the obesity market, although additional development and regulatory work remain. Phase 2 COURAGE Trial results
• Positive Sentiment: Analysts became more constructive. Jefferies raised its price target to $930 and maintained a buy rating, while Argus upgraded REGN to buy with an $850 target. These actions suggest improved confidence in the company’s pipeline and longer-term growth prospects.
• Neutral Sentiment: Ubamatamab showed promising but early oncology results. The therapy produced a 73% objective response rate and 11-month median progression-free survival in 11 heavily pretreated patients with low-grade serous ovarian cancer. The small, early-stage dataset is encouraging but requires confirmation in larger studies. Ubamatamab ovarian cancer study
• Negative Sentiment: Investors appeared underwhelmed by the ovarian cancer data. Despite the high response rate, reports indicated that REGN came under pressure after the early-stage readout, likely reflecting concerns about the limited patient sample, durability, and the distance to possible approval.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses human genetics, antibody technology and other biological research platforms to develop treatments in areas including eye diseases, cancer, cardiovascular and metabolic disorders, inflammatory diseases, infectious diseases and rare conditions.

Regeneron’s marketed products include EYLEA and EYLEA HD for certain retinal diseases; Dupixent, developed and commercialized with Sanofi, for multiple allergic and inflammatory conditions; Libtayo for certain cancers; Praluent for high cholesterol; Kevzara for rheumatoid arthritis and other inflammatory diseases; Evkeeza for homozygous familial hypercholesterolemia; and Veopoz for a rare immune-mediated disorder.